GlassScriptPhysician profile
Mark Gilbert Braverman
NPI 1164685277
$3,626.75
in general payments reported to CMS, 2019-2025
23 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $180 · 2021: $150 · 2022: $599 · 2023: $646 · 2024: $659 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $562.80 | 2019-2024 | |
| Irhythm Technologies, INC. | $445.56 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Abiomed | $417.97 | 2023-2025 | Impella |
| Boston Scientific Corporation | $373.39 | 2019-2025 | Bodyguardian, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $352.42 | 2019-2025 | Farxiga |
| Amgen INC. | $241.82 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.84 | 2021-2024 | Lifevest |
| Abbott Laboratories | $203.04 | 2022-2025 | Assurity |
| Medtronic Vascular, INC. | $138.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $126.42 | 2019-2022 | |
| Pfizer INC. | $121.56 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $76.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.51 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.44 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $44.62 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.18 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.02 | 2022-2023 | Camzyos |
| Kestra Medical Technology Services, INC. | $27.87 | 2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $23.82 | 2024 | Inspire |
| Innovation Technologies INC | $15.19 | 2025 | Irrisept |
| Astellas Pharma US INC | $14.02 | 2019 | |
| Agepha Pharma Fz LLC | $13.02 | 2024 | Lodoco |
| Amarin Pharma, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gilbert Braverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.